Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive (FLT3mut+) Acute Myeloid Leukemia (AML)
- Resource Type
- Abstract
- Source
- In
Blood 13 November 2019 134 Supplement 1:5085-5085 - Subject
- Language
- ISSN
- 0006-4971